ApoB and apoM - New aspects of lipoprotein biology in uremia-induced atherosclerosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Christina Christoffersen, Emil D. Bartels, Annemarie Aarup Pedersen, Lars Bo Nielsen, Tanja X. Pedersen

Chronic kidney disease affects as much as 13% of the population, and is associated with a markedly increased risk of developing cardiovascular disease. One of the underlying reasons is accelerated development of atherosclerosis. This can be ascribed both to increased occurrence of traditional cardiovascular risk factors, and to risk factors that may be unique to patients with chronic kidney disease. The latter is reflected in the observation that the current treatment modalities, mainly directed against traditional risk factors, are insufficient to prevent cardiovascular disease in the patient with chronic kidney disease. This review discusses mechanisms accelerating uremic atherosclerosis with a specific focus on the putative roles of apolipoprotein(apo)s B and M that may be particularly important in patients with chronic kidney disease.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Pharmacology
Vol/bind816
Sider (fra-til)154-160
Antal sider7
ISSN0014-2999
DOI
StatusUdgivet - dec. 2017

ID: 178848251